Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$798M |
| 2 |
Netflix
NFLX
|
+$608M |
| 3 |
UnitedHealth
UNH
|
+$517M |
| 4 |
Apple
AAPL
|
+$461M |
| 5 |
GE Vernova
GEV
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$527M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 3 |
Meta Platforms (Facebook)
META
|
+$362M |
| 4 |
Advanced Micro Devices
AMD
|
+$328M |
| 5 |
Palantir
PLTR
|
+$327M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 15.79% |
| 3 | Consumer Discretionary | 12.36% |
| 4 | Financials | 11.53% |
| 5 | Industrials | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2576
CarParts.com
PRTS
$66.4M
| $882K | ﹤0.01% |
119,200
+8,130
| +7% | +$69.5K |
2021 Q3
15 quarters
|
|
2577
AMES National
ATLO
$279M
| $874K | ﹤0.01% |
49,084
+600
| +1% | +$10.4K |
2014 Q4
42 quarters
|
|
2578
Franklin Street Properties
FSP
$35.4M
| $870K | ﹤0.01% |
530,583
+54,800
| +12% | +$91.3K |
2014 Q3
43 quarters
|
|
2579
JPMorgan Active Growth ETF
JGRO
$10.3B
| $869K | ﹤0.01% |
10,100
-6,100
| -38% | -$474K |
2024 Q2
4 quarters
|
|
2580
DELISTED
Trinseo
TSE
| $867K | ﹤0.01% |
278,000
+22,100
| +9% | +$72.8K |
2022 Q1
13 quarters
|
|
2581
Viking Therapeutics
VKTX
$3.63B
| $867K | ﹤0.01% |
32,700
-295,000
| -90% | -$7.77M |
2025 Q1
1 quarter
|
|
2582
Distribution Solutions Group
DSGR
$1.62B
| $866K | ﹤0.01% |
31,520
-29,080
| -48% | -$780K |
2014 Q3
43 quarters
|
|
2583
Silicon Motion
SIMO
$8.95B
| $864K | ﹤0.01% |
11,500
-46,300
| -80% | -$2.63M |
2023 Q3
7 quarters
|
|
2584
Better Online Solutions
BOSC
$32.2M
| $862K | ﹤0.01% |
177,642
-7,122
| -4% | -$29.2K |
2017 Q4
30 quarters
|
|
2585
Whitehawk Therapeutics
WHWK
$201M
| $857K | ﹤0.01% |
458,222
-3,900
| -0.8% | -$6.79K |
2019 Q2
24 quarters
|
|
2586
Manhattan Bridge Capital
LOAN
$39.2M
| $852K | ﹤0.01% |
155,828
+5,900
| +4% | +$30.7K |
2014 Q4
42 quarters
|
|
2587
Energy Services of America
ESOA
$194M
| $852K | ﹤0.01% |
85,700
-10,700
| -11% | -$102K |
2022 Q2
12 quarters
|
|
2588
Origin Bancorp
OBK
$1.59B
| $851K | ﹤0.01% |
23,800
+2,400
| +11% | +$79.5K |
2019 Q2
24 quarters
|
|
|
SVA
2589
DELISTED
Sinovac Biotech, Ltd
SVA
| $849K | ﹤0.01% |
+1,312,520
| New | +$849K |
2025 Q2
0 quarters
|
|
2590
Home BancShares
HOMB
$5.65B
| $846K | ﹤0.01% |
29,739
-47,700
| -62% | -$1.33M |
2025 Q1
1 quarter
|
|
2591
Halliburton
HAL
$27.1B
| $846K | ﹤0.01% |
+41,500
| New | +$870K |
2025 Q2
0 quarters
|
|
2592
DELISTED
Mersana Therapeutics
MRSN
| $844K | ﹤0.01% |
114,008
+80,411
| +239% | +$707K |
2021 Q4
14 quarters
|
|
2593
HEICO Corp Class A
HEI.A
$31.2B
| $843K | ﹤0.01% |
3,258
-11,000
| -77% | -$2.41M |
2013 Q2
48 quarters
|
|
2594
Invesco S&P 500 High Beta ETF
SPHB
$1B
| $839K | ﹤0.01% |
8,600
-29,500
| -77% | -$2.49M |
2024 Q4
2 quarters
|
|
2595
Fastly Inc
FSLY
$4.67B
| $838K | ﹤0.01% |
+118,741
| New | +$796K |
2025 Q2
0 quarters
|
|
2596
Koppers
KOP
$821M
| $836K | ﹤0.01% |
26,000
-18,400
| -41% | -$528K |
2023 Q1
9 quarters
|
|
2597
Candel Therapeutics
CADL
$761M
| $828K | ﹤0.01% |
+163,600
| New | +$842K |
2025 Q2
0 quarters
|
|
2598
Goldgroup Mining
GORO
$576M
| $826K | ﹤0.01% |
338,598
-56,250
| -14% | -$122K |
2021 Q2
16 quarters
|
|
2599
DELISTED
Generation Bio
GBIO
| $826K | ﹤0.01% |
258,078
+70,011
| +37% | +$270K |
2021 Q4
14 quarters
|
|
2600
iShares Russell Top 200 Value ETF
IWX
$3.74B
| $825K | ﹤0.01% |
+9,800
| New | +$789K |
2025 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2025 Portfolio in Review
As of Q2 2025, Renaissance Technologies held 4,018 positions worth $75.2B, up 14% from $66.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies's Q2 2025 filing shows 612 new, 1,577 increased, 1,314 reduced and 496 closed positions. Its largest new stake was UnitedHealth: 1,352,129 shares worth $422M. The largest sale was Broadcom, an estimated $527M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Renaissance Technologies's largest Q2 2025 buy was UnitedHealth: 1,352,129 shares worth $422M.
- Renaissance Technologies added most to NVIDIA in Q2 2025, an estimated $798M increase.
- Renaissance Technologies's biggest Q2 2025 reduction was Broadcom, cutting an estimated $527M.
- Renaissance Technologies fully exited Advanced Micro Devices in Q2 2025, selling an estimated $328M.
- Renaissance Technologies's ten largest holdings make up 12% of its $75.2B portfolio in Q2 2025.
- Renaissance Technologies opened 612 new positions and closed 496 in Q2 2025.
- Renaissance Technologies's portfolio value rose 14% quarter-over-quarter to $75.2B.
Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.